Betmiga 50 Mg

Betmiga 50 Mg

Description:

Betmiga 50 mg is a prescription oral medicine containing mirabegron, a beta-3 adrenergic agonist used for the management of overactive bladder (OAB). It helps relax the detrusor muscle in the bladder, increasing bladder capacity and reducing episodes of urgency, urge urinary incontinence, and frequent urination. Betmiga 50 mg prolonged-release tablets are designed for once-daily dosing to provide sustained symptom control throughout the day and night. This product is intended for adult patients and must be used under medical supervision.

Indications:

• Treatment of overactive bladder (OAB) in adults.
• Relief of symptoms associated with OAB, including urge urinary incontinence (sudden involuntary loss of urine).
• Reduction of urinary urgency (sudden, compelling desire to pass urine).
• Reduction of increased urinary frequency (need to urinate more often than usual, including nocturia).
• May be used as an alternative in patients who cannot tolerate or do not respond adequately to antimuscarinic agents due to anticholinergic side effects.

Active Ingredients / Key Components:

• Mirabegron – 50 mg per prolonged-release tablet.
• Other inactive ingredients (excipients) are present to form the prolonged-release tablet core and coating; specific excipient list and concentrations , please check the product leaflet or the manufacturer’s official website. Please refer to the official package leaflet for the full excipient list.

Dosage & Administration / How to Use:

• Usual adult dose: 50 mg mirabegron (one Betmiga 50 mg prolonged-release tablet) taken once daily, or as directed by your physician.
• Swallow the tablet whole with a glass of water. Do not crush, chew, or split the tablet, as this may affect the prolonged-release properties.
• Betmiga 50 mg can be taken with or without food, preferably at the same time each day for consistent effect.
• In patients with moderate renal impairment, severe renal impairment, or moderate hepatic impairment, a lower starting dose (e.g., 25 mg) may be recommended; follow your doctor’s specific instructions.
• Do not exceed the prescribed dose. Do not stop taking the medication without consulting your healthcare provider, even if symptoms improve.
• If you miss a dose, take it as soon as you remember on the same day. If it is almost time for your next dose, skip the missed dose and continue with your regular schedule. Do not take a double dose to make up for a missed one.
• Use in children and adolescents: Not recommended unless specifically prescribed by a specialist, as safety and efficacy data are limited.

Clinical Benefits:

• Helps reduce episodes of urge urinary incontinence, improving bladder control and confidence in daily activities.
• Decreases urinary urgency and frequency, including nighttime urination, contributing to better sleep quality and daytime comfort.
• Provides a non-anticholinergic treatment option for overactive bladder, which may be better tolerated in patients who experience dry mouth, constipation, or other antimuscarinic side effects.
• Once-daily prolonged-release formulation offers convenient dosing and sustained symptom relief throughout the day.

Warnings & Contraindications:

• Contraindicated in patients with known hypersensitivity to mirabegron or any component of the formulation.
• Use with caution in patients with severe uncontrolled hypertension; mirabegron can increase blood pressure. Regular blood pressure monitoring may be required.
• Use with caution in patients with renal impairment or hepatic impairment; dose adjustment may be necessary. Follow your doctor’s recommendations.
• Use with caution in patients with bladder outlet obstruction or those taking antimuscarinic medications, as there is a risk of urinary retention.
• Inform your doctor about all medications you are taking, especially other drugs that affect blood pressure, CYP2D6 substrates, or medications for heart rhythm, as interactions may occur.
• Pregnancy and breastfeeding: Use only if clearly needed and prescribed by a physician. Safety data in pregnancy and lactation are limited; discuss risks and benefits with your healthcare provider.
• Not intended for self-medication. This is a prescription medicine and should only be used under medical supervision.
• Consult your doctor before use if pregnant, nursing, taking medications, or have medical conditions such as hypertension, heart disease, liver disease, kidney disease, or urinary obstruction.
• Keep out of reach of children.

Side Effects:

• Common side effects may include increased blood pressure, urinary tract infection, headache, nasopharyngitis (cold-like symptoms), dry mouth, constipation, and dizziness.
• Less common side effects can include palpitations, tachycardia (fast heartbeat), abdominal pain, nausea, diarrhea, and joint pain.
• Serious but rare side effects may include severe hypertension, allergic reactions (rash, itching, swelling of face or tongue, difficulty breathing), or urinary retention (inability to pass urine). Seek immediate medical attention if these occur.
• If you experience persistent or bothersome side effects, or any new or unusual symptoms, contact your doctor or pharmacist promptly.

Storage Instructions:

Store in a cool, dry place away from direct sunlight. Keep container tightly closed. Keep out of reach of children. Do not use after the expiry date stated on the packaging. Store at or below the temperature specified on the product carton (exact temperature range not available in the provided information; refer to the official packaging).

Specifications:

• Form: Prolonged-release tablet (oral use).
• Strength: 50 mg mirabegron per tablet.
• Pack size: 30 prolonged-release tablets per pack (Betmiga 50 mg 30 prolonged r. tabs.).
• Intended use: Prescription medicine for adult overactive bladder management.

Disclaimer:
All pharmacy products are intended for general use only and do not replace professional medical advice, diagnosis, or treatment. Always consult a healthcare provider before use. Results may vary, and no specific outcomes are guaranteed. Products are not intended to diagnose, treat, cure, or prevent any disease unless stated. Follow label instructions carefully, as misuse may cause adverse effects. Compliance with local laws is the customer’s responsibility.